FDA Sets Peptide Impurity Thresholds as Low as 0.10%, Oath Research Analysis Finds

FDA guidance for synthetic peptide drugs requires identification of impurities above 0.10% and caps new impurities at 0.5% — U.S. FDA, 2021GILBERT, Ariz., June 30, 2026 /PRNewswire/ — Oath Research, a Gilbert, Arizona–based research peptide supplier, today released…

Read the full release →

News provided by PR Newswire.